Navigation Links
Valeritas Announces Appointment of New CEO

Former Johnson & Johnson Senior Executive Kristine Peterson to Take Helm

PARSIPPANY, N.J., June 1 /PRNewswire/ -- Valeritas, Inc., a medical technology company committed to the development and commercialization of innovative drug delivery solutions, announced today that it has hired Kristine Peterson to serve as its Chief Executive Officer.

Peterson brings 26 years of industry experience to Valeritas, with her most recent successes as Company Group Chair of Johnson & Johnson's Biotech Business where she was directly responsible for commercial, research & development and supply chain/manufacturing for biotech, oncology, immunology, and cell therapy.

"We are thrilled that Kris has joined the Valeritas executive team," said Vaughn Kailian, Executive Chairman of the Board, Valeritas, Inc and Managing Director of MPM Capital. "She exhibits a broad range of experience and leadership qualities, along with a deep compassion for patients and their challenges. This exceptional skill set makes her the ideal leader to take Valeritas to the next level as a fully operational medical technology company."

"Joining Valeritas at this pivotal time in its lifecycle is a great privilege," said Peterson. "With the company's strong financial backing, a potentially life changing first product, and a broad technology platform that can support a wide array of therapeutic options, Valeritas is positioned to be a highly successful company."

Peterson joined Johnson & Johnson in August 2004 as Executive Vice President, Pharmaceutical Group Strategic Marketing with responsibility for developing global launch plans for Internal Medicine, Metabolics, Central Nervous System, Oncology, Virology, Anemia and Pain franchises. Prior to joining J&J, Peterson was Senior Vice President, Commercial Operations, Biovail Corporation and President Biovail Pharmaceuticals. In this role, she was responsible for US, Canada, Nutravail, Business Development and New Product Planning. Earlier, Peterson spent 20 years with Bristol-Myers Squibb where she held assignments of increasing responsibility in sales, marketing and general management including running a Cardiovascular/Metabolics business unit and a generics division.

Peterson is currently a member of the Biotechnology Industry Organization Board (Health Governing Section) and a member of the Greater Philadelphia Life Sciences Congress Board. She is also an advisor to the Healthcare Businesswoman's Association Metro Chapter.

About Valeritas, Inc.

Valeritas is a medical technology company committed to developing and commercializing innovative drug delivery solutions that contribute to clinical and humanistic outcomes for patients, with an initial focus on the treatment of diabetes. Valeritas' medical technologies portfolio is headlined by the h-Patch(TM) Technology. The first use of the h-Patch(TM) technology will be the V-Go(TM) disposable insulin delivery device for continuous delivery both at a pre-set basal rate and for on-demand bolus dosing at mealtimes.

In addition to V-Go(TM), Valeritas' delivery technology portfolio includes the h-Patch(TM) for the delivery of other compounds beyond insulin, the Mini-Ject(TM) Pre-Filled Needle-Free Delivery System, and the Micro-Trans(TM) Microneedle Transdermal Delivery Patch. These technologies, when combined with certain compounds, are designed to provide unique products that allow precise dosing in previously difficult to treat conditions.

Headquartered in Parsippany, N.J., Valeritas operates its R&D and manufacturing in a state-of-the-art facility in Shrewsbury, Massachusetts. Valeritas primary investors include: MPM Capital, Pitango Venture Capital, Abingworth, US Venture Partners, Onset Ventures, Advanced Technology Ventures, HLM Venture Partners, CHL Medical Partners, and Kaiser Permanente Ventures.

SOURCE Valeritas, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Valeritas Hires Trade and Distribution Industry Expert for the Launch of the h-Patch(TM) Disposable Insulin Delivery Device
2. Valeritas Hires Senior Account Management Industry Expert for the Launch of the h-Patch(TM) Disposable Insulin Delivery Device
3. John Timberlake, Valeritas Executive Vice President and General Manager, Named Executive of the Year by the Diabetes Foundation
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
8. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
Post Your Comments:
(Date:10/11/2017)... ... October 11, 2017 , ... ... has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and ... of osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular ...
(Date:10/10/2017)... California (PRWEB) , ... October 10, 2017 , ... Dr. ... speaking at his local San Diego Rotary Club. The event entitled ... Diego, CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined by ...
(Date:10/10/2017)... ... 2017 , ... The Pittcon Program Committee is pleased to ... who have made outstanding contributions to analytical chemistry and applied spectroscopy. Each award ... conference and exposition for laboratory science, which will be held February 26-March 1, ...
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving Tree Wellness Center ... the needs of consumers who are incorporating medical marijuana into their wellness and ... , As operators of two successful Valley dispensaries, The Giving Tree’s two founders, ...
Breaking Biology Technology:
(Date:4/11/2017)... 2017 No two people are believed ... New York University Tandon School of Engineering and ... that partial similarities between prints are common enough ... phones and other electronic devices can be more ... lies in the fact that fingerprint-based authentication systems ...
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC , ... that the United States Patent and Trademark Office (USPTO) ... covers the linking of an iris image with a ... and represents the company,s 45 th issued patent. ... is very timely given the multi-modal biometric capabilities that ...
Breaking Biology News(10 mins):